Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1992 Aug;45(8):664–667. doi: 10.1136/jcp.45.8.664

Proliferating cell nuclear antigen and S phase fraction in endometrial stromal sarcoma.

J B Schofield 1, J Mansi 1, R S Camplejohn 1, D P Lane 1, C Fisher 1
PMCID: PMC495140  PMID: 1357005

Abstract

AIMS: To investigate the value of immunohistochemical staining for the cell cycle protein proliferating cell nuclear antigen (PCNA) and flow cytometric S phase fraction in determining prognosis in endometrial stromal sarcoma, graded according to mitotic count. METHODS: Seventeen endometrial stromal sarcomas from 13 patients treated at the Royal Marsden Hospital were analysed. Serial 5 microns sections were cut for haematoxylin and eosin and immunohistochemical staining for PCNA, performed using the murine monoclonal antibody PC10. PCNA positivity was expressed as a percentage of the total number of cells (PCNA index). Flow cytometric analysis was performed on nuclei extracted from paraffin wax sections. RESULTS: In the five patients who died of disease within five years, PCNA index varied between < 1% and 60% (mean 21%) and S phase fraction ranged from 11.3 and 20.1 (mean 13.8). Four patients who were apparently cured showed PCNA indices ranging from < 1% to 5% (mean 1.75%) and S phase fraction ranging from 1.4 to 3.5 (mean 2.3); and three patients alive with disease showed PCNA indices ranging from 1% to 15% (mean 8.6%) and S phase fraction ranging from 1.4 to 3.5 (mean 2.3). One patient who died from indolent local disease after nine years showed a PCNA of 1 or less and an S phase fraction of 0.9. CONCLUSIONS: PCNA staining was variable and therefore not a reliable prognostic indicator, but a high PCNA index was only found in those patients dying of disease within five years. A stronger association was seen between S phase fraction and prognosis; this also correlated well with histological grade determined by mitotic count. In individual borderline cases that are between low and high grade categories, these procedures may be useful.

Full text

PDF
664

Images in this article

665Image
on p.665
665Image
on p.665

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. August C. Z., Bauer K. D., Lurain J., Murad T. Neoplasms of endometrial stroma: histopathologic and flow cytometric analysis with clinical correlation. Hum Pathol. 1989 Mar;20(3):232–237. doi: 10.1016/0046-8177(89)90129-9. [DOI] [PubMed] [Google Scholar]
  2. Baisch H., Göhde W., Linden W. A. Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle. Radiat Environ Biophys. 1975 Jun 13;12(1):31–39. doi: 10.1007/BF02339807. [DOI] [PubMed] [Google Scholar]
  3. Camplejohn R. S., Macartney J. C., Morris R. W. Measurement of S-phase fractions in lymphoid tissue comparing fresh versus paraffin-embedded tissue and 4',6'-diamidino-2 phenylindole dihydrochloride versus propidium iodide staining. Cytometry. 1989 Jul;10(4):410–416. doi: 10.1002/cyto.990100408. [DOI] [PubMed] [Google Scholar]
  4. Covens A. L., Nisker J. A., Chapman W. B., Allen H. H. Uterine sarcoma: an analysis of 74 cases. Am J Obstet Gynecol. 1987 Feb;156(2):370–374. doi: 10.1016/0002-9378(87)90286-9. [DOI] [PubMed] [Google Scholar]
  5. De Fusco P. A., Gaffey T. A., Malkasian G. D., Jr, Long H. J., Cha S. S. Endometrial stromal sarcoma: review of Mayo Clinic experience, 1945-1980. Gynecol Oncol. 1989 Oct;35(1):8–14. doi: 10.1016/0090-8258(89)90002-4. [DOI] [PubMed] [Google Scholar]
  6. George M., Pejovic M. H., Kramar A. Uterine sarcomas: prognostic factors and treatment modalities--study on 209 patients. Gynecol Oncol. 1986 May;24(1):58–67. doi: 10.1016/0090-8258(86)90008-9. [DOI] [PubMed] [Google Scholar]
  7. Hall P. A., Levison D. A. Review: assessment of cell proliferation in histological material. J Clin Pathol. 1990 Mar;43(3):184–192. doi: 10.1136/jcp.43.3.184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hall P. A., Levison D. A., Woods A. L., Yu C. C., Kellock D. B., Watkins J. A., Barnes D. M., Gillett C. E., Camplejohn R., Dover R. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol. 1990 Dec;162(4):285–294. doi: 10.1002/path.1711620403. [DOI] [PubMed] [Google Scholar]
  9. KOSS L. G., SPIRO R. H., BRUNSCHWIG A. ENDOMETRIAL STROMAL SARCOMA. Surg Gynecol Obstet. 1965 Sep;121:531–537. [PubMed] [Google Scholar]
  10. Katz L., Merino M. J., Sakamoto H., Schwartz P. E. Endometrial stromal sarcoma: a clinicopathologic study of 11 cases with determination of estrogen and progestin receptor levels in three tumors. Gynecol Oncol. 1987 Jan;26(1):87–97. doi: 10.1016/0090-8258(87)90074-6. [DOI] [PubMed] [Google Scholar]
  11. Larson B., Silfverswärd C., Nilsson B., Pettersson F. Endometrial stromal sarcoma of the uterus. A clinical and histopathological study. The Radiumhemmet series 1936-1981. Eur J Obstet Gynecol Reprod Biol. 1990 May-Jun;35(2-3):239–249. doi: 10.1016/0028-2243(90)90168-z. [DOI] [PubMed] [Google Scholar]
  12. Mansi J. L., Ramachandra S., Wiltshaw E., Fisher C. Endometrial stromal sarcomas. Gynecol Oncol. 1990 Jan;36(1):113–118. doi: 10.1016/0090-8258(90)90120-a. [DOI] [PubMed] [Google Scholar]
  13. Norris H. J., Taylor H. B. Mesenchymal tumors of the uterus. I. A clinical and pathological study of 53 endometrial stromal tumors. Cancer. 1966 Jun;19(6):755–766. doi: 10.1002/1097-0142(196606)19:6<755::aid-cncr2820190604>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  14. Silverberg S. G. Reproducibility of the mitosis count in the histologic diagnosis of smooth muscle tumors of the uterus. Hum Pathol. 1976 Jul;7(4):451–454. doi: 10.1016/s0046-8177(76)80058-5. [DOI] [PubMed] [Google Scholar]
  15. Taina E., Mäenpä J., Erkkola R., Ikkala J., Söderström O., Viitanen A. Endometrial stromal sarcoma: a report of nine cases. Gynecol Oncol. 1989 Feb;32(2):156–162. doi: 10.1016/s0090-8258(89)80027-7. [DOI] [PubMed] [Google Scholar]
  16. Waseem N. H., Lane D. P. Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci. 1990 May;96(Pt 1):121–129. doi: 10.1242/jcs.96.1.121. [DOI] [PubMed] [Google Scholar]
  17. Woods A. L., Hall P. A., Shepherd N. A., Hanby A. M., Waseem N. H., Lane D. P., Levison D. A. The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in primary gastrointestinal lymphomas and its relationship to histological grade, S+G2+M phase fraction (flow cytometric analysis) and prognosis. Histopathology. 1991 Jul;19(1):21–27. doi: 10.1111/j.1365-2559.1991.tb00890.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES